1. FDA approves Sarepta’s DMD drug that it had previously rejected — Biogen chalks up another failure — The House passes the Lower Drug Costs Now Act, but it’s unlikely to become law — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Good place to work?

Discussion in 'Dendrite' started by Anonymous, Mar 10, 2012 at 10:40 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Thinking of interviewing at Cegidem but am concerned about the short and long term outlook. Does anyone have any thoughts on this and which area(s) might be in trouble or questionable at bet.

    Thanks!
     

  2. Anonymous

    Anonymous Guest

    You're kidding right???

    Stay away there are no long or short term prospects here.
     
  3. Anonymous

    Anonymous Guest

    Thanks! Didn't think the outlook was so poor!